Andra AP fonden Sells 24,400 Shares of Eli Lilly and Company $LLY

Andra AP fonden trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 52.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,800 shares of the company’s stock after selling 24,400 shares during the quarter. Andra AP fonden’s holdings in Eli Lilly and Company were worth $16,994,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Ascent Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after purchasing an additional 12 shares during the last quarter. Willner & Heller LLC raised its holdings in Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after purchasing an additional 13 shares in the last quarter. Braun Bostich & Associates Inc. lifted its position in shares of Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after buying an additional 13 shares during the last quarter. Rise Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after buying an additional 13 shares in the last quarter. Finally, Occidental Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HSBC boosted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $950.00.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 4,314 shares of company stock valued at $2,766,929. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $938.13 on Friday. The firm has a market capitalization of $886.89 billion, a price-to-earnings ratio of 61.32, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a fifty day moving average of $796.15 and a 200 day moving average of $775.03. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.